Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Current Assets (2023 - 2025)

Historic Current Assets for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $27.9 million.

  • Zhengye Biotechnology Holding's Current Assets changed N/A to $27.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $27.9 million, marking a year-over-year change of. This contributed to the annual value of $24.7 million for FY2024, which is 771.57% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Current Assets stood at $27.9 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Current Assets registered a high of $27.9 million during Q2 2025, and its lowest value of $24.7 million during Q4 2024.
  • Moreover, its 3-year median value for Current Assets was $26.3 million (2023), whereas its average is $26.3 million.
  • The largest annual percentage gain for Zhengye Biotechnology Holding's Current Assets in the last 5 years was 594.76% (2024), contrasted with its biggest fall of 594.76% (2024).
  • Over the past 3 years, Zhengye Biotechnology Holding's Current Assets (Quarter) stood at $26.3 million in 2023, then dropped by 5.95% to $24.7 million in 2024, then increased by 12.66% to $27.9 million in 2025.
  • Its Current Assets stands at $27.9 million for Q2 2025, versus $24.7 million for Q4 2024 and $26.3 million for Q4 2023.